Compare Logitech International SA (LOGI) vs 10X Genomics Inc (TXG) Price & Performance

Logitech (LOGI) trades at $101.50, down 0.67% on the day, with a neutral technical signal and key support at $100. The company demonstrates strong fundamentals with a 16.28% net income margin and consistent earnings beats in recent quarters. Recent product launches like the Zone Vibe Pro headset and partnership with SEGA for Crazy Taxi: World Tour highlight ongoing innovation. Cash flow trends show robust operational performance, with 2025 operating cash flow of $842.56 million.

The outlook is cautiously optimistic, supported by a consensus price target of $107.00 implying modest upside. Investment opportunities include sustained profitability and strategic growth initiatives, while risks involve competitive pressures and potential supply chain disruptions as noted in recent CEO commentary. Analyst sentiment is mixed with a Hold-heavy consensus, reflecting balanced near-term expectations.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.